VivoSeq
Oncology

Differentiated Thyroid Gland Carcinoma

1

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Differentiated Thyroid Gland Carcinoma is an early-stage landscape with 1 program across 2 companies. The most active players are Merck & Co., Jochen Lorch.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 2J

Jochen Lorch

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Zanzalintinib

Merck & Co.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Not yet recruiting1 · 50%

Clinical Trials

Trial Activity

A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer
Recruiting·NNorthwestern University·Phase 2·NCT06959641·33 enrolled
Personalized Cancer Support for Young Adults
Not yet recruiting·UUniversity of Michigan Rogel Cancer Center·Preclinical·NCT07529080·142 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)